relapsed/refractory mantle cell lymphoma
Showing 1 - 25 of >10,000
Mantle-cell Lymphoma Trial (Polatuzumab, bendamustin und rituximab)
Not yet recruiting
- Mantle-cell Lymphoma
- Polatuzumab, bendamustin und rituximab
- (no location specified)
May 11, 2023
Mantle Cell Lymphoma Refractory Trial (Ibrutinib, Venetoclax, Navitoclax)
Not yet recruiting
- Mantle Cell Lymphoma Refractory
- Ibrutinib
- +3 more
- (no location specified)
May 16, 2023
Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Houston (Low Dose Radiation Therapy)
Recruiting
- Recurrent Mantle Cell Lymphoma
- Refractory Mantle Cell Lymphoma
- Low Dose Radiation Therapy
-
Houston, TexasM D Anderson Cancer Center
Jan 30, 2023
Mantle Cell Lymphoma Trial in Duarte (drug, procedure, biological)
Not yet recruiting
- Mantle Cell Lymphoma
- Acalabrutinib
- +8 more
-
Duarte, CaliforniaCity of Hope Medical Center
Sep 20, 2023
Relapsed/Refractory Mantle Cell Lymphoma Trial in Worldwide (brexucabtagene autoleucel, Cyclophosphamide, Fludarabine)
Active, not recruiting
- Relapsed/Refractory Mantle Cell Lymphoma
- brexucabtagene autoleucel
- +3 more
-
Gilbert, Arizona
- +31 more
Jan 26, 2023
Blastoid Variant Mantle Cell Lymphoma, CCND1 Protein Overexpression, CD20 Positive Trial in Houston (Acalabrutinib, Venetoclax)
Recruiting
- Blastoid Variant Mantle Cell Lymphoma
- +8 more
-
Houston, TexasM D Anderson Cancer Center
Dec 5, 2022
Lymphoma, Mantle-Cell, Recurrent Lymphoma, Mantle-Cell Trial in United States (ABT-199 and Ibrutinib Combination)
Completed
- Lymphoma, Mantle-Cell
- Recurrent Lymphoma, Mantle-Cell
- ABT-199 and Ibrutinib Combination
-
Duarte, California
- +3 more
May 22, 2022
Relapsed or Refractory B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL) Trial in Beijing
Recruiting
- Relapsed or Refractory B-cell Lymphoma
- +6 more
-
Beijing, ChinaBeijing Cancer Hospital
Feb 6, 2023
Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Rochester (procedure, drug, biological)
Not yet recruiting
- Recurrent Mantle Cell Lymphoma
- Refractory Mantle Cell Lymphoma
- Biopsy
- +10 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Jun 9, 2023
Relapsed/Refractory Mantle Cell Lymphoma Trial in Worldwide (Fludarabine, Cyclophosphamide, Brexucabtagene autoleucel)
Recruiting
- Relapsed/Refractory Mantle Cell Lymphoma
- Fludarabine
- +2 more
-
Gilbert, Arizona
- +40 more
Jan 6, 2023
Lymphoma, B-Cell, Relapsed Cancer, Refractory Lymphoma Trial in Boston (Adaptive Bridging Radiation Therapy (ABRT))
Not yet recruiting
- Lymphoma, B-Cell
- +7 more
- Adaptive Bridging Radiation Therapy (ABRT)
-
Boston, MassachusettsDana-Farber Cancer Institute
Aug 16, 2023
Chronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell Lymphoma Trial in India (Acalabrutinib capsule)
Active, not recruiting
- Chronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell Lymphoma
- Acalabrutinib capsule
-
Ahmedabad, India
- +12 more
Feb 2, 2023
Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial (Pirtobrutinib, LV20.19 CAR T cells)
Not yet recruiting
- Non Hodgkin Lymphoma
- +5 more
- Pirtobrutinib
- LV20.19 CAR T cells
- (no location specified)
Aug 4, 2023
Mantle Cell Lymphoma, Lymphoma Trial in United States (BR-I (bendamustine, rituximab, ibrutinib), VEN (Venetoclax))
Active, not recruiting
- Mantle Cell Lymphoma
- Lymphoma
- BR-I (bendamustine, rituximab, ibrutinib)
- VEN (Venetoclax)
-
Basking Ridge, New Jersey
- +6 more
Feb 3, 2022
Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma Trial run by the NCI (Obinutuzumab, Venetoclax, Magrolimab)
Recruiting
- Follicular Lymphoma
- +4 more
- Obinutuzumab
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 20, 2023
Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Boston (CD79b-19 CAR T cells,
Not yet recruiting
- Non-hodgkin Lymphoma
- +9 more
- CD79b-19 CAR T cells
- +2 more
-
Boston, MassachusettsMassachusetts General Hospital
Sep 6, 2023
Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Houston (Biospecimen Collection, Follow-Up)
Recruiting
- Recurrent Mantle Cell Lymphoma
- Refractory Mantle Cell Lymphoma
- Biospecimen Collection
- Follow-Up
-
Houston, TexasM D Anderson Cancer Center
Dec 5, 2022
Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Duarte, New Haven (Copanlisib Hydrochloride,
Recruiting
- Recurrent Mantle Cell Lymphoma
- Refractory Mantle Cell Lymphoma
- Copanlisib Hydrochloride
- Venetoclax
-
Duarte, California
- +1 more
Aug 3, 2022
Lymphoma, Mantle-Cell, Lymphoma, Lymphoproliferative Disorders Trial (Zilovertamab, Ibrutinib, Placebo)
Not yet recruiting
- Lymphoma, Mantle-Cell
- +7 more
- Zilovertamab
- +2 more
- (no location specified)
Jun 21, 2022
Mantle Cell Lymphoma Trial in Beijing (DTRMWXHS-12)
Active, not recruiting
- Mantle Cell Lymphoma
-
Beijing, ChinaPeking University Cancer Hospital
Aug 18, 2021
Aggressive B-Cell Non-Hodgkin's Lymphoma, Aggressive B-Cell NHL, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Trial
Not yet recruiting
- Aggressive B-Cell Non-Hodgkin's Lymphoma
- +4 more
- (no location specified)
Dec 16, 2022
Mantle Cell Lymphoma, MCL Trial in United States (Tafasitamab, Lenalidomide)
Recruiting
- Mantle Cell Lymphoma
- MCL
-
Basking Ridge, New Jersey
- +6 more
Mar 27, 2023